$UFPT

UFP TECHNOLOGIES INC

AlphAI earnings readsecond quarter of 2026 · AUG 3UFP Technologies Announces Record Q2 ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
1
0

No SEC Form 4 filings for $UFPT in the last 30 days.

See all $UFPT insider activity →
Low

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.

Is UFP Technologies (UFPT) Undervalued After Argus Lifted Its Price Target?

Argus raised its price target for UFP Technologies (UFPT) to $334, citing strong recent performance and growth prospects. The stock has gained 34.60% year-to-date and 54.03% over one year. Analysts estimate a fair value of $355, but the stock trades at a P/E of 32.2x, higher than its industry average. The company's expansion and medical sector focus drive optimism, though risks include customer concentration and integration challenges.

UFP Technologies, Inc. acquired CI Medical Inc.

UFP Technologies, Inc. (UFPT) completed the acquisition of CI Medical Inc. on September 7, 2026. The company's stock has seen a 5-day change of 288.79 USD, a 1st Jan change of +0.79%, and a year-to-date change of +30.07%.

UFPT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning UFPT (UFP TECHNOLOGIES INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent UFPT coverage spans insider activity, earnings and financial news.

What's driving UFPT

AlphAI scores every news story that mentions UFPT with an AI model for sentiment and relevance, and aggregates insider trades from UFP TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $UFPT

Score

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.

Is UFP Technologies (UFPT) Undervalued After Argus Lifted Its Price Target?

Argus raised its price target for UFP Technologies (UFPT) to $334, citing strong recent performance and growth prospects. The stock has gained 34.60% year-to-date and 54.03% over one year. Analysts estimate a fair value of $355, but the stock trades at a P/E of 32.2x, higher than its industry average. The company's expansion and medical sector focus drive optimism, though risks include customer concentration and integration challenges.

$UFPTMed

UFP Technologies Targets 12%-18% Growth as Medical Device M&A Pipeline Builds

UFP Technologies (UFPT) aims for 12%-18% annual growth via organic growth and acquisitions, targeting medical device markets. The company expects gross margins of 28%-31% and operating margins of 17%-20%. UFP is evaluating 5-10 acquisition opportunities with EBITDA ranging from $5M to $30M. Inventory is expected to decline in Q4 due to seasonal factors.

Related tickers